MacroGenics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5560991094
USD
3.17
0.25 (8.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Arcutis Biotherapeutics, Inc.
Arbutus Biopharma Corp.
Nurix Therapeutics, Inc.
ARS Pharmaceuticals, Inc.
MacroGenics, Inc.
Coherus BioSciences, Inc.
Erasca, Inc.
Oric Pharmaceuticals, Inc.
Cullinan Therapeutics, Inc.
KalVista Pharmaceuticals, Inc.
Icosavax, Inc.

Why is MacroGenics, Inc. ?

1
Poor long term growth as Net Sales has grown by an annual rate of 10.53% and Operating profit at 5.74% over the last 5 years
2
The company has declared negative results in Mar'2025 after 2 consecutive positive quarters
  • NET PROFIT(HY) At USD -19.43 MM has Grown at -3,112.25%
  • OPERATING CASH FLOW(Y) Lowest at USD -162.47 MM
  • NET SALES(HY) At USD 95.08 MM has Grown at -21.75%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 39.29%, its profits have risen by 22.3%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is MacroGenics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
MacroGenics, Inc.
61.73%
-0.41
98.57%
S&P 500
13.68%
0.71
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
10.53%
EBIT Growth (5y)
5.74%
EBIT to Interest (avg)
-128.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.88
Sales to Capital Employed (avg)
0.94
Tax Ratio
1.72%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.94
EV to EBIT
-1.11
EV to EBITDA
-1.19
EV to Capital Employed
-31.51
EV to Sales
0.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-113.26%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
NET SALES(Q)

At USD 72.84 MM has Grown at 76.05%

PRE-TAX PROFIT(Q)

At USD 16.82 MM has Grown at 290.35%

NET PROFIT(Q)

At USD 16.82 MM has Grown at 284.86%

-29What is not working for the Company
NET PROFIT(HY)

At USD -19.43 MM has Grown at -3,112.25%

OPERATING CASH FLOW(Y)

Lowest at USD -162.47 MM

NET SALES(HY)

At USD 95.08 MM has Grown at -21.75%

ROCE(HY)

Lowest at -81.13%

RAW MATERIAL COST(Y)

Grown by 15.7% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -58.41 %

INTEREST(Q)

Highest at USD 3.34 MM

Here's what is working for MacroGenics, Inc.

Net Sales
At USD 72.84 MM has Grown at 76.05%
over average net sales of the previous four periods of USD 41.37 MM
MOJO Watch
Near term sales trend is extremely positive

Net Sales (USD MM)

Pre-Tax Profit
At USD 16.82 MM has Grown at 290.35%
over average net sales of the previous four periods of USD -8.84 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 16.82 MM has Grown at 284.86%
over average net sales of the previous four periods of USD -9.1 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Here's what is not working for MacroGenics, Inc.

Operating Cash Flow
Lowest at USD -162.47 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest
At USD 3.34 MM has Grown at 316.71%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest
Highest at USD 3.34 MM
in the last five periods and Increased by 316.71% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio
Highest at -58.41 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 15.7% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Non Operating Income
Highest at USD 0.09 MM
in the last five periods
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating income